Recro Pharma, Inc. (NASDAQ:REPH) is reporting second quarter earnings results on Monday 10th August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.16 per share.
For the full year, analysts predict revenues of $ 81.11 million, while looking forward to loss of $ 0.55 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 80.00 million ~ $ 85.00 million
Click Here For More Historical Outlooks Of Recro Pharma, Inc.
Previous Quarter Performance
Recro Pharma, Inc. unveiled loss for the first quarter of $ 0.33 per share, from the revenue of $ 21.78 million. The quarterly revenues lowered 13.12 percent compared with the same quarter last year. Street analysts expected Recro Pharma, Inc. to report loss of $ 0.03 per share on revenue of $ 19.45 million for the first quarter. The bottom line results missed street analysts by $ 0 or , at the same time, top line results outshined analysts by $ 2.33 million or 11.98 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Recro Pharma, Inc.
Stock Performance
According to the previous trading day, closing price of REPH was $ 4.40, representing a 10.28 % increase from the 52 week low of $ 3.99 and a 77.1 % decrease over the 52 week high of $ 19.21.
The company has a market capital of $ 103.69 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”REPH” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Recro Pharma, Inc. will be hosting a conference call at 8:00 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.recropharma.com
Recro Pharma, Inc. operates as a specialty pharmaceutical company. It operates through two divisions, an Acute Care, and Contract Development and Manufacturing (CDMO).
